UNDERWRITER COMMON STOCK PURCHASE WARRANT HOTH THERAPEUTICS, INC.Hoth Therapeutics, Inc. • March 25th, 2020 • Pharmaceutical preparations
THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date set forth above and on or prior to 5:00 p.m. (New York City time) on March 24, 2025 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______[1] shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain underwriting agreement, dated as of March 24, 2020, by and among the Company, Laidlaw & Company (UK) Ltd., as representative of
HOTH THERAPEUTICS, INC. 1,449,275 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 25th, 2020 • Hoth Therapeutics, Inc. • Pharmaceutical preparations • New York
Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), subject to the terms and conditions herein, proposes to sell to the underwriters (the “Underwriters”) named in Schedule I attached to this agreement (this “Agreement”), on a best efforts basis, 1,449,275 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).
